Herpes simplex virus type 1 (HSV-1) virions, like those of all herpesviruses, are composed of a nucleocapsid harboring the double-stranded linear DNA genome, a proteinaceous layer surrounding the nucleocapsid termed the tegument, and a host-derived lipid membrane envelope that contains viral glycoproteins. The tegument layer is a unique feature among herpesviruses and is composed of at least 20 different viral proteins of various stoichiometries. Tegument proteins have been shown to play a variety of roles in infection including the regulation of viral and host gene expression and the promotion of virus assembly and egress (6, 19, 34, 39) . Because tegument proteins enter the cell upon fusion of the viral envelope with the host cell membrane, they can potentially exert their activities prior to viral gene expression to provide herpesviruses an advantage early in infection.
VP22, encoded by the U L 49 gene, is one of the most abundant HSV-1 tegument proteins, with an average of 2,000 copies present in each virion (18, 22) . VP22 is conserved among the alphaherpesviruses and has been studied in HSV-1, herpes simplex virus type 2 (HSV-2), bovine herpesvirus, and pseudorabies virus (PRV). Localization studies suggest that this protein is dynamically trafficked, as VP22 is present within both the cytoplasm and nucleus at different times in infection (16, 36) . Although VP22 is present in infected cells in both phosphorylated and nonphosphorylated isoforms, only hypophosphorylated VP22 is incorporated into virions (4, 17, 21, 24, 30, 35, 36) . In addition, VP22 has been shown to induce the stabilization and hyperacetylation of microtubules (15) and to interact with a number of proteins including histones H1 and H4 (40) , the viral glycoproteins gE, gM, and gD (7, 20) , and the viral transactivator of immediate-early gene expression, VP16 (14) .
Despite these interesting observations, the role of VP22 in HSV-1 infection remains unclear. An HSV-1 recombinant virus that expresses a truncated form of VP22 (HSV-1 RF177) expresses low levels of the amino-terminal 212 residues of the 301-residue VP22 (37) . The truncated form of VP22 expressed by RF177 showed normal cellular localization and was incorporated into extracellular virions. In addition, single-step growth kinetics, capsid assembly, and viral egress of RF177 were nearly indistinguishable from those of wild-type HSV-1. However, RF177 viral plaques were reduced in size by nearly 40% at 48 h postinfection compared to plaques produced by the wild-type virus, suggesting a role for VP22 in HSV-1 cellcell spread. Recently, an HSV-1 U L 49-null mutant was constructed and described (13) . Although VP22 was found to alter the expression, localization, and virion incorporation of the viral transactivator ICP0, no difference in plaque size was reported. Thus, the role(s) of VP22 in HSV-1 infection, and specifically in viral spread, requires further study.
To determine the contribution of VP22 to HSV-1 infection, we generated HSV-1 U L 49-null and U L 49-repaired viruses and characterized their growth relative to the wild-type parental virus in both cultured cells and the mouse cornea. Single-step growth analyses indicated that VP22 was not required for efficient virus assembly while multistep growth analyses, plaque measurements, and mouse corneal spread assays showed that VP22 was required for efficient viral spread. Interestingly, the absence of VP22 did not appear to affect either intracellular virus production or cell-cell spread but decreased extracellular virus at least 90%. Thus, the defect in viral spread associated with the U L 49-null virus is due to decreased secondary infection by an extracellular route.
MATERIALS AND METHODS
Viruses and cells. Viral stocks of wild-type HSV-1F, the U L 49 deletion virus, and the U L 49 repair virus were propagated exclusively on V49 cells, a Veroderived cell line that constitutively expresses VP22 (37) . Vero and V49 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 4.0 mM L-glutamine, 4.5 g/liter glucose, 125 U/ml penicillin, 0.125 mg/ml streptomycin, and either 10% newborn calf serum or 10% fetal bovine serum, respectively.
Plasmid construction. The recombinant plasmid used to generate the U L 49R virus by shuttle mutagenesis was constructed as follows. First, the ApoI-BamHI segment (HSV-1 bp 104768 to 107022) of the BamHI F-fragment of HSV-1F was subcloned from pRB128 (a gift from Bernard Roizman) into pUC19. Next, the ApoI site was replaced with a BamHI site using the ApoI/BamHI linker 5Ј-AA TTGGATCC-3Ј and standard cloning methods. This fragment was then released via BamHI digest and cloned into the BamHI site of pST76K_SR. The shuttle mutagenesis plasmid pST76K_SR contains a Kan r gene for positive selection upon transformation, a recA gene for recombination in Escherichia coli, a temperature-sensitive origin of replication for selection of cointegrates, and an sacB sucrose-sensitivity gene for selection of cointegrate resolution (1, 5 (29) was replaced with an FRT-BamHI site, was generated according to the method of Lee et al. (25) as follows. E. coli EL250 cells, which harbor (i) a defective prophage in which the exo, bet, and gam recombination and nuclease-inhibition genes are under the control of the cI857 temperaturesensitive repressor and (ii) an arabinose-inducible flpe recombinase gene, were transformed with pYEbac102. A chloramphenicol-resistant (Cm r ) clone that maintained the full-length HSV-1(F) genome as a BAC was identified and used for the mutagenesis. A linear recombination fragment containing a Kan r gene flanked by Flp recognition target (FRT) sites, one BamHI site, and short sequences homologous to regions up-and downstream of the U L 49 ORF was generated by PCR and gel purified. pKD13, a plasmid containing a FRT-Kan r -FRT-BamHI cassette (9) was used as a template for the PCR. The primers used for the PCR were 5Ј-ACGCAACGCCAACACCGAATGAACCCCTGTTGGTG CTTTATTGTCTGGGTACGGAATTCCGGGGATCCGTCGAC-3Ј and 5Ј-ACC CAGGCCTAATTGTCCGCGCATCCGACCCTAGCGTGTTCGTGCGTGTAG GCTGGAGCTGCTTC-3Ј (Integrated DNA Technologies, Coralville, IA); nucleotides in italics are homologous to the BAC target sequences up-and downstream, respectively, of U L 49; nucleotides in Roman type are homologous to the FRT-Kan r -FRT-BamHI template cassette of pKD13; and nucleotides in boldface indicate the BamHI site. To prepare E. coli EL250 cells carrying pYEbac102 for electroporation, liquid cultures were grown at 30°C in LuriaBertani (LB) medium containing 30 g/ml chloramphenicol (CHL) to an optical density at 600 nm of 0.6; cultures were temperature shifted to 42°C for 15 min to induce Exo, Beta, and Gam expression and then chilled on ice, washed three times with 10% ice-cold glycerol, and concentrated 500-fold. A total of 75 l of competent cells was transformed via electroporation (2.3 kV, 200 ⍀, and 25F) with ϳ500 ng of the gel-purified recombination fragment. Following growth at 30°C on LB agar plates containing 30 g/ml CHL and 50 g/ml kanamycin (KAN), Cm r Kan r recombinants were genotypically verified by restriction fragment length polymorphism (RFLP) of alkaline lysis-extracted BAC DNA. Next, the Kan r gene was excised through Flp-mediated recombination between the flanking FRT sites after induction of Flp recombinase by growth in 0.1% arabinose overnight at 30°C. Kanamycin-sensitive clones were identified through replica plating on LB agar plates containing either CHL (30 g/ml) or KAN (50 g/ml), and the BACs were again genotypically verified by RFLP of alkaline lysis-extracted BAC DNA. The resulting BAC was named pYEbac102-U L 49 Ϫ . The U L 49R BAC was constructed by reintroducing the U L 49 ORF into pYEbac102-U L 49
Ϫ in its native position using a RecA-based method of shuttle mutagenesis (5, 31 Ϫ were transformed with 200 ng of the shuttle plasmid pJB386 (see above) and incubated at 30°C on a bacterial shaker in LB medium. Cells were plated on LB agar containing CHL (30 g/ml) and KAN (50 g/ml) and incubated overnight at 42°C to select for integration of the shuttle plasmid into pYEbac102-U L 49
Ϫ via one of the U L 49 flanking regions. Cointegrates were genotypically verified via RFLP of BAC DNA extracted from liquid cultures grown at 42°C in LB containing 30 g/ml CHL and 50 g/ml KAN. To resolve the cointegrates, positive clones were grown in LB plus CHL (30 g/ml) for 4 h at 37°C, sucrose was then added to a final concentration of 10% (wt/vol), and the cultures were shaken for another 4 h at 37°C. Cells were plated on LB agar containing 30 g/ml CHL and 10% sucrose and incubated overnight at 30°C to select for loss of the shuttle plasmid. Kanamycin-sensitive, chloramphenicol-resistant clones identified through replica plating on LB agar plates containing either 50 g/ml KAN or 30 g/ml CHL were genotypically verified through RFLP of alkaline lysis-extracted BAC DNA. The resulting BAC was named pYEbac102-U L 49R.
The U L 49.5 Ϫ BAC, in which HSV-1 bp 106746 to 106928 were deleted, was generated according to the method of Tischer et al. (43) as follows. A linear recombination fragment containing a Kan r gene, an I-SceI endonuclease site, and short sequences homologous to regions up-and downstream of HSV-1F bp 106746 and 106928 was generated by PCR and gel purified. The primers used for the PCR were 5Ј-ACACAGGGCGGGTTCAGGCGTGCCCGGCAGCCAGTA GCCTGCCGCTAAGGCGACGAGCAATAGGGATAACAGGGTAATCGA TTT-3Ј and 5Ј-GGGCGGGCCTGTTGTTTGTCTTGCTCGTCGCCTTAGC GGCAGGCTACTGGCTGCCGGGCAGCCAGTGTTACAACCAATTAAC C-3Ј (Integrated DNA Technologies, Coralville, IA); nucleotides in italics are homologous to the BAC target sequences upstream of HSV-1(F) bp 106746, nucleotides in Roman type are homologous to the BAC target sequences downstream of HSV-1F bp 106928, and nucleotides in boldface are homologous to the Kan r -I-SceI template cassette. E. coli EL250 cells carrying pYEbac102 were transformed via electroporation (2.3 kV, 200 ⍀, 25F) with ϳ200 ng of the gel-purified recombination fragment. Following growth at 30°C on LB agar plates containing 30 g/ml CHL and 50 g/ml KAN, Cm r Kan r recombinants were genotypically verified by RFLP of alkaline lysis-extracted BAC DNA. A genotypically correct clone was transformed with pBAD (43) which encodes an arabinose-inducible I-SceI restriction endonuclease, and transformants were selected via growth at 30°C on LB agar plates containing 30 g/ml CHL, 50 g/ml KAN, and 100 g/ml ampicillin. Next, the Kan r gene was excised through Redmediated recombination following induction of I-SceI with 0.5% arabinose. Kanamycin-sensitive clones were identified through replica plating on LB agar plates containing either CHL (30 g/ml) or KAN (50 g/ml), and the BACs were again genotypically verified by RFLP of alkaline lysis-extracted BAC DNA. The resulting BAC was named pYEbac102-U L 49. Ϫ , or the U L 49R virus at a multiplicity of infection (MOI) of 5 and held at 34°C until a cytopathic effect was visible in ϳ80% of the cells. Cells were washed with phosphate-buffered saline (PBS), pelleted, resuspended in 2.5 ml of Tris-EDTA buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA), and allowed to swell on ice. Cells were lysed by the addition of NP-40 to 1% and spun to pellet cellular debris. The supernatant containing DNA-filled capsids was transferred to a new tube, and viral DNA was released by incubation at 37°C for 30 min in the presence of 0.5 mg/ml proteinase K and 1% sodium dodecyl sulfate (SDS). Viral DNA was then extracted four times with phenol-chloroform-isoamyl alcohol (48:48:4), precipitated with sodium acetate and ethanol, and resuspended in water.
The genetically manipulated regions of the U L 49 Ϫ and U L 49R genomes were amplified by PCR from purified viral DNA, and nucleotide sequencing was performed to confirm that the desired mutations had been introduced.
Purified viral DNAs were digested with BamHI or EcoRV, separated by electrophoresis through a 1% agarose gel, visualized with ethidium bromide, and transferred to Hybond-Nϩ nylon membrane (Amersham Biosciences, Piscataway, NJ). Probes used in Southern hybridization were generated from the HSV-1 BamHI F-fragment (HSV-1 bp 98967 to 107022) or the ApoI-BamHI segment of the HSV-1 BamHI F-fragment (HSV-1 bp 104768 to 107022) by [␣- Ϫ , or U L 49R viruses at an MOI of 0.1 at 37°C for 48 h. Virions were pelleted through a 30% sucrose cushion, resuspended in 0.5 ml of 10 mM Tris-Cl (pH 7.4), and separated through a 14% to 26% Dextran T10 (Amersham Pharmacia Biotech, Uppsala, Sweden) gradient. Gradients were fractionated and titrated on Vero cells to determine the PFU/ml of each fraction and probed with an anti-VP5 antibody via immunoblotting (see below) to determine the relative amount of VP5 present in each fraction.
Intracellular virions were prepared from Vero cells infected with WT, U L 49 Ϫ , or U L 49R viruses at an MOI of 0.1 at 37°C for 36 h. Cells were pelleted, washed with PBS, and frozen at Ϫ80°C. Cells were later thawed, resuspended in 1.0 mM PO 4 (Na) (pH 7.4), and lysed by dounce homogenization. Sucrose [1.25 M in 1.0 mM PO 4 (Na), pH 7.4] was added to stabilize nuclei, which were then pelleted by centrifugation. Virions present in the supernatant were pelleted through a sucrose cushion and separated through a Dextran T10 gradient as for extracellular virions. Virions observed as a light-scattering band were removed by needle and syringe, resuspended in 10 mM Tris-Cl (pH 7.4), and pelleted by centrifugation. The virion pellet was resuspended in SDS-PAGE sample buffer and boiled for 5 min.
Immunoblot analyses. Cell lysates were prepared by infection of 25-cm 2 flasks of Vero cells with WT, U L 49 Ϫ , or U L 49R viruses at an MOI of 5 at 37°C. At 18 hpi, cells were collected, washed with PBS, boiled in SDS-PAGE sample buffer, and sonicated briefly. Cell lysates and virion preparations were separated by SDS-12% PAGE, and the proteins were transferred to nitrocellulose or polyvinylidene difluoride membranes. Free binding sites on the membranes were blocked by 10% skim milk in PBS before the addition of either anti-VP22 (4) (diluted 1:5,000), anti-VP16 (sc-17547; Santa Cruz Biotechnology, Santa Cruz, CA) (diluted 1:500), anti-pU L 28 (3) (diluted 1:1,000), anti-VP5 (8) (diluted 1:3,000), anti-ICP0 (Abcam, Cambridge, MA) (diluted 1:5,000), anti-gE (23) (diluted 1:2,500), anti-gD (Rumbaugh-Goodwin Institute for Cancer Research, Plantation, FL) (diluted 1:1,000), or anti-␤-actin (Santa Cruz Biotechnology, Santa Cruz, CA) (diluted to 0.5 g/ml) antibodies. After extensive washing to remove unbound antibody, bound antibodies were detected with anti-rabbit (Amersham Biosciences, Piscataway, NJ) or anti-goat (Jackson Immunoresearch Laboratories, West Grove, PA) immunoglobulin G conjugated to horseradish peroxidase and visualized by ECL (Amersham Biosciences, Piscataway, NJ) chemiluminescence on Pierce CL-X Posure film (Pierce Biotechnology, Rockford, IL).
Plaque area determination in cultured cells. Vero cells were grown in 35-cm 2 dishes, infected with WT, U L 49 Ϫ , or U L 49R viruses at 10 PFU/dish, overlaid with medium 199 containing 1% newborn calf serum (medium 199V), and held at 37°C for 44 h. Cells were fixed with 90% acetone and analyzed by indirect immunofluorescence using a rabbit polyclonal anti-gM primary antibody (2) and a fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody (Jackson Immunoresearch Laboratories, West Grove, PA). Plaques were visualized under a fluorescence microscope (Zeiss Axiovert 25), and 70 plaques from each virus were photographed with a digital camera (Zeiss AxioCam HRc). Plaque areas were determined using ImageJ software available from the National Institutes of Health (http://rsb.info.nih.gov/ij/index.html). Statistical analyses (two-tailed t tests) were performed using Microsoft Excel software.
Single-step and multistep growth analyses. . At a later date, the cells were thawed, scraped into 0.5-ml thrice-autoclaved milk, and briefly sonicated; virus was titrated on Vero cells to determine intracellular growth kinetics.
To study the kinetics of intracellular multistep growth in the absence of secondary infections initiated by virus released to the medium, 199V medium containing 0.3% human immunoglobulin (Sigma-Aldrich, St. Louis, MO) was added to cells following infection and citrate buffer-199V medium washes. At the indicated times postinfection, cells were scraped, pelleted, and washed three times with PBS to remove the neutralizing human immunoglobulins. Cell pellets were resuspended in 0.5 ml of thrice-autoclaved skim milk, briefly sonicated, and frozen at Ϫ80°C. At a later date, virus in the resuspended pellets was titrated on Vero cells.
Particle-PFU analyses. Extracellular virions were prepared from clarified overlying medium of Vero cells infected with WT, U L 49 Ϫ , or U L 49R viruses at an MOI of 0.1 at 37°C for 48 h. Virions were pelleted through a 30% sucrose cushion, resuspended in TBSal (10 mM Tris-HCl, pH 7.5, 200 mM NaCl, 2.6 mM KCl, 20 mM MgCl, 1.8 mM CaCl), and briefly sonicated. Part of each virion preparation was titrated on Vero cells to determine the PFU/ml. Part of each virion preparation was diluted in ultrapure H 2 O, mixed with a known quantity of 0.3-m polystyrene latex beads (Ladd Research, Williston, VT), and spotted and dried on Formvar and carbon-coated nickel grids. After drying, the samples were stained with 2% aqueous uranyl-acetate and viewed with a Philips 201 transmission electron microscope. Viral particles and latex beads were counted, with the beads serving as an internal control, and the number of viral particles/ml of preparation was calculated. The number of viral particles/PFU was calculated from the number of viral particles/ml and number of PFU/ml of each virion preparation.
Corneal viral spread analyses. All procedures involving animals adhered to the Society for Neuroscience Guidelines for the Use of Animals in Research and the guidelines of the University of California San Francisco Committee on Animal Research. Male BALB/c mice 6 to 8 weeks old were anesthetized with an intraperitoneal injection of Avertin (28), followed by topical corneal administration of 0.05% proparacaine and 1% atropine in the eye. The eyes were blotted with sterile cotton, and immediately the corneas were scarified in a grid pattern of 10 horizontal and 10 vertical strokes with a 27-gauge needle. A 5-l drop of virus in minimal essential medium containing 106 PFU of virus was applied to the cornea. Anesthesia was maintained for 20 to 30 min following inoculation to allow for viral adsorption. The animals were monitored daily and showed no behavioral signs of infection.
The mice were allowed to survive 24 (n ϭ 3), 48 (n ϭ 3), or 72 (n ϭ 3) h after infection. They were reanesthetized with Avertin and killed by intracardiac perfusion with normal saline. The corneas were dissected and prepared for immunohistochemistry according to standard procedure (33) . In brief, the corneas were first incubated overnight in blocking solution composed of 3% normal goat serum, 0.1% Triton-100 in PBS (pH 7.2). They were incubated overnight in primary antiserum (horseradish peroxidase-conjugated polyclonal antiserum raised in rabbits against human HSV-1; 1:100 dilution) (Accurate Chemical and Scientific Corp., Westbury, N.Y.), and the presence of HSV antigens was determined with nickel-enhanced diaminobenzine. The corneas were flat mounted on glass slides, and viral spread was estimated using digitized photographs of corneal whole mounts at ϫ25 magnification and ImageJ software. For each measurement the distance from the edge of the scratch to the farthest boundary of contiguous infected cells was traced. Measurements were collected from at least five fields for each eye.
RESULTS

Generation of U L 49 deletion and repair viruses.
To identify the role(s) of VP22 during HSV-1 infection, we generated both a U L 49-null virus (U L 49 Ϫ ) that lacks the entire U L 49 ORF and a repair virus (U L 49R) in which the U L 49 ORF is restored using an HSV-1F BAC system (42) as described in Materials and Methods. The deletion in the U L 49-null virus spanned bp 105480 to 106396, a region from 5 bp before the start codon to 5 bp after the stop codon of the U L 49 ORF. This entire sequence was restored to its original location in the U L 49R virus.
When propagated on V49 cells and analyzed on Vero cells, the U L 49 Ϫ plaque phenotype (see below) remained consistent. However, when the U L 49
Ϫ virus was propagated on Vero or rabbit skin cells, some of the plaques became dramatically larger within the first two to three passages (http://www.vet .cornell.edu/labs/baines/). Therefore, all of the present studies were performed with virus stocks propagated on the complementing V49 cell line.
To verify the expected genotypes of the recombinant viruses, viral DNA was purified, digested with BamHI, and electrophoretically separated through a 1% agarose gel. The digested DNAs were transferred to a nitrocellulose membrane and probed with [␣-
32 P]dCTP-labeled BamHI F-fragment derived from WT HSV-1(F). Figure 1A shows the expected size of the U L 49-containing BamHI F-fragment of the WT and U L 49R viruses compared to that of the U L 49
Ϫ virus in which the U L 49 ORF was replaced by an FRT-BamHI site. Figures 1B and 1C show the ethidium bromide-stained agarose gel and Southern hybridization, respectively, of BamHI-digested viral DNA. As expected, the BamHI F-fragment (predicted size of 8,054 bp) was present in the digested WT and U L 49R viral DNAs and hybridized with the BamHI F-fragment probe (Fig. 1B and C,  asterisks) . In contrast, BamHI fragments of approximately 6,500 bp (filled circle) and 700 bp (filled square) present in the digested U L 49
Ϫ viral DNA hybridized with the BamHI Ffragment probe. These results were consistent with the expected BamHI fragment sizes (6,512 bp and 724 bp) of the U L 49 deletion as designed. To ensure that the nucleotide sequences of the U L 49
Ϫ and U L 49R viruses were correct, the genetically manipulated regions of the genomes were amplified from purified viral DNA by PCR and sequenced. All nucleotide sequences were found to be correct as designed.
To confirm the deletion and repair of the U L 49 ORF, the expression of VP22 in cells infected with the recombinant viruses was examined. Vero cells were infected at an MOI of 5 with WT, U L 49 Ϫ , or U L 49R virus and then collected at 18 hpi and lysed. Proteins within the lysates were analyzed by immunoblotting with an anti-VP22 polyclonal antibody (4). As expected, VP22 was present in lysates of WT-and U L 49R-infected cells but absent from lysates of U L 49 Ϫ -infected cells (Fig. 2, top) .
To ensure that the deletion of U L 49 did not affect expression of the U L 48 gene product VP16, immunoblots of the above lysates were probed with an anti-VP16 polyclonal antibody (Fig. 2, middle) . As a loading control, these immunoblots were also probed with a polyclonal antibody directed against another late protein encoded by the U L 28 gene (Fig. 2, bottom) . Ϫ , and U L 49R viruses, and plaques were observed 44 h after infection (Fig. 4A) . Quantitative analysis of these viral plaques showed that the U L 49 Ϫ virus produced plaques that were, on average, 5% the area of those formed by the WT virus (Fig. 4B) . Even with the high inherent variability in plaque size among the plaques examined, this difference was statistically significant (P Ͻ 0.000001). By contrast, the U L 49R virus produced plaques that were approximately 78% the size of those formed by the WT virus, but this difference was not statistically significant. To determine whether the reduced plaque size observed with the U L 49 Ϫ virus was due to a defect in virus assembly, egress, and/or cell-cell spread, further experiments were performed.
Characterization of growth properties of the U L 49 ؊ virus in cultured cells. To determine whether the small plaques produced by the U L 49 Ϫ virus are due to a defect in virus assembly, single-step growth analyses were performed. Vero cells infected at an MOI of 5 with the WT, U L 49 Ϫ , and U L 49R viruses were collected at various times postinfection and lysed, and intracellular virus was quantified by plaque assay (Fig. 5A) . Medium overlaying the infected cell monolayers was clarified and assayed separately (Fig. 5B) . Single-step growth kinetics of both intra-and extracellular U L 49 Ϫ virus did not differ significantly from those of either the WT or U L 49R viruses. Together, the above data indicate that the reduced plaque size observed with the U L 49
Ϫ virus is not due to a defect in virus assembly.
Many viral growth defects are subtle enough to only be observed after multiple rounds of infection. Also, viral growth initiated by high MOIs, such as in the above experiment, is measured in the presence of some amount of VP22 delivered Ϫ , or U L 49R viruses for 18 h were separated by SDS-PAGE and probed for the presence of VP22 (top) and VP16 (middle). As a loading control, the immunoblot was also probed with an antibody directed against pU L 28 (bottom).
from the infecting virions that were propagated on a complementing cell line. To minimize such effects and further study the role of VP22 in viral growth, we performed multistep growth analyses in cells infected with 0.001 PFU/cell. To study extracellular virus as a component of viral spread, we titrated the overlying medium and infected cell monolayers separately. Figure 6A shows that intracellular U L 49 Ϫ virus titers were decreased, up to ϳ11-fold at 48 hpi, compared to both the WT and U L 49R viruses. Extracellular U L 49 Ϫ virus titers were also decreased, again up to ϳ11-fold at 48 hpi, compared to the WT and U L 49R viruses as shown in Fig. 6B .
Virion release is decreased in the absence of VP22. The decrease in U L 49
Ϫ intra-and extracellular multistep growth could be due to one or more of the following mechanisms: (i) decreased release of U L 49 Ϫ virions into the medium, resulting in decreased secondary infection and spread through the cell monolayer; (ii) decreased infectivity of individual extracellular U L 49 Ϫ virions, resulting in decreased secondary infection; (iii) decreased or defective virus assembly within U L 49
Ϫ -infected cells, resulting in fewer intra-and extracellular infectious particles; and (iv) decreased spread from infected cells to adjacent cells (cell-cell infection), resulting in decreased spread through the monolayer. To differentiate between these possibilities, we performed multistep intracellular growth analyses in the presence of neutralizing antibody in the overlaying medium. This treatment dramatically reduces extracellular virus and therefore focuses the analysis onto viral spread in the absence of secondary infections from extracellular particles. As shown in Fig. 6C , when extracellular virus was eliminated from multistep growth, the U L 49 Ϫ virus generated intracellular titers approximately equivalent to those of the WT and U L 49R viruses. Thus, the above data show the viral spread defect observed upon U L 49
Ϫ virus infection was primarily due to decreased viral release and/or decreased infectivity of extracellular Ϫ , and U L 49R viruses at an MOI of 0.001 PFU/cell for 1 h to allow virus adsorption. The cells were then washed extensively with citrate buffer to neutralize and remove unbound virus, overlaid with medium, and held at 37°C. Cells infected for intracellular multistep growth analysis in the presence of neutralizing antibody were overlaid with medium containing 0.3% human gamma globulins. At the indicated times postinfection, these cells were pelleted, washed three times with PBS to remove the neutralizing antibody, and lysed. Also at the indicated times postinfection, medium was removed from cells grown in the absence of neutralizing antibody and clarified. Intracellular virus was titrated from the cell lysates and extracellular virus was titrated from the clarified medium. The growth curves shown represent the means and standard deviations (error bars) of three independent experiments. Growth curves in the upper panels were performed at different times using different passages of Vero cells than those of the lower panel. Therefore, titers between upper and lower panels are not comparable.
analyses of these gradient fractions using an antibody against the major capsid protein, VP5, showed that the U L 49 Ϫ gradient fractions also contained less VP5 (Fig. 7B) , indicating that U L 49 Ϫ viral infections produce fewer extracellular particles as well as fewer extracellular PFU compared to WT or U L 49R infections. To further compare the infectivity of extracellular U L 49 Ϫ virions to extracellular wild-type and U L 49R virions, we performed particle-PFU analyses. The particle-to-PFU ratios of purified WT, U L 49 Ϫ , and U L 49R extracellular virions were 234:1, 550:1, and 418:1, respectively; these ratios were not readily distinguishable within the high inherent variability of this technique. These findings indicate that extracellular U L 49 Ϫ particles are not measurably less infectious than WT or U L 49R extracellular particles and, together with the above data on multistep viral growth in the presence and absence of neutralizing antibody, show that the spread defect associated with the U L 49 Ϫ virus is largely attributable to decreased viral release.
To correlate the decreased viral release of the U L 49-null virus with the effect of extracellular virus on WT HSV-1 spread, we examined the effect of neutralizing antibody on WT plaque size. We found that in the presence of 1% human immunoglobulin, WT HSV-1 produces plaques that are 15% the size of those produced in the absence of neutralizing antibody (data not shown), showing that extracellular virus contributes greatly to HSV-1 plaque size and viral spread.
Protein composition of U L 49
؊ virions. The defective viral release observed upon infection with the U L 49 Ϫ virus could be a direct or indirect consequence of the absence of VP22. Differences in intracellular virion composition could contribute to differences in viral release. Therefore, we investigated whether VP22 contributes indirectly to virion release, through a possible role in virion assembly, by examining the protein composition of WT, U L 49 Ϫ , and U L 49R intracellular virions. The left panel of Fig. 8 shows a Coomassie-stained SDS-polyacrylamide gel separation of purified intracellular virions, whereas the right panels show immunoblot analyses of the same samples. The locations of the probed proteins are aligned with their counterparts in the Coomassie-stained gel. The major capsid protein, VP5, was probed as a loading control. Recently, Elliott and others showed that VP22 is absolutely required for the incorporation of ICP0 into virions (13, 38) . We found that although ICP0 was decreased in U L 49 Ϫ virions, VP22 was not absolutely required for its incorporation. In HSV-1, VP22 has been shown to interact with both VP16 and gD (7, 14) . As previously reported (13), we found that the absence of VP22 had no effect on incorporation of VP16, whereas levels of gD were decreased in U L 49
Ϫ virions compared to WT and U L 49R virions. Although PRV VP22 was found to interact with PRV gE, virion incorporation of gE was not affected in a PRV U L 49 deletion virus (20) . In contrast, we found that levels of gE were dramatically decreased in HSV-1 U L 49
Ϫ virions compared to Ϫ virus. The above data indicate that VP22 is involved in, but not required for, incorporation of ICP0, gD, and gE into HSV-1 virions. In addition, the protein composition of VP22 Ϫ virions varies between HSV-1 and PRV, suggesting that the role(s) VP22 plays in virion assembly varies between the two systems.
VP22 is required for efficient viral spread in the mouse cornea. Many HSV-1 proteins exhibit functional redundancy and are therefore deemed nonessential when studied in cultured cells, but they exhibit more dramatic phenotypes in live animals. To determine whether VP22 is essential for viral growth in vivo, we analyzed viral spread in the mouse cornea. Corneas in live mice were scarified and infected with ϳ100 PFU of WT, U L 49 Ϫ , or U L 49R virus. At 24 or 48 hpi, the mice were sacrificed, the corneas were dissected, and the presence of infectious virus was revealed by immunohistochemistry with an HSV-specific antibody. At both time points the U L 49
Ϫ virus spread only ϳ60% of the distance spread by the WT and U L 49R viruses ( Fig. 9 and Table 1 ). The far-right panels of Fig.  9 show whole flat-mounted corneas photographed at lower magnification and illustrate the decreased size of corneal lesions produced upon infection with the U L 49-null virus (Fig.  9C ) compared to the lesions produced by the WT and U L 49R viruses ( Fig. 9I and F, respectively) . The U L 49 Ϫ virus formed isolated rosettes of infected cells, whereas the WT and U L 49R viruses formed extensive borders of infected cells along the length of the scarification. These data identify a role for VP22 in HSV-1 viral spread in vivo as well as in cultured cells.
DISCUSSION
Although many studies have focused on identifying the biological properties of HSV-1 VP22 and its homologs in other herpesviruses, the role this protein plays in HSV-1 infection is unclear. To address this problem, we generated two recombinant viruses, one lacking the entire U L 49 gene and one containing a restored U L 49 gene, and characterized their growth. In this report we show that VP22 is required for efficient viral spread during infection of both cultured cells and the mouse cornea.
Role of VP22 in viral spread in cultured cells. While singlestep intracellular and extracellular growth analyses did not indicate a defect in virus assembly for the U L 49-null virus, plaques produced by this virus in cultured cells were reduced in size by an average of 95% compared to the WT and U L 49-repaired viruses. A similar, though less dramatic, phenotype was previously observed with an HSV-1 U L 49 truncation mutant that expresses low levels of the amino-terminal 212 residues of VP22 (37) . This virus, HSV-1 RF177, produced plaques in cultured cells that were reduced in size by nearly 40% compared to those produced by the parental WT virus. It is currently not known whether the reduced plaque size observed with this virus is due to the lack of the carboxy-terminal 89 residues of VP22 or to the low expression level of the truncated protein, and, therefore, we cannot attribute the function of VP22 in viral spread to a particular domain of the protein. In any case, the two studies are in agreement in defining a role for VP22 in viral spread of HSV-1.
Recently, an HSV-1 recombinant virus in which the U L 49 gene was replaced with the gene encoding green fluorescent protein was reported (13). Elliott et al. constructed their U L 49-null virus on a VP22-complementing cell line because the recombinant virus could not be generated on noncomplementing cells, and it was therefore suggested that the WT virus maintained a growth advantage over the U L 49-null virus. However, once the U L 49-null virus was generated, the authors observed that VP22 was not necessary for virus growth on noncomplementing Vero cells and, thus, performed all further experiments with virus stocks propagated on noncomplementing cells. A decrease in plaque size was not reported for this virus.
We have also observed that VP22 is dispensable for growth on Vero cells. However, we have noted with interest that while U L 49 Ϫ stocks propagated on VP22-complementing cells consistently produced plaques ϳ5% the size of those produced by the WT and U L 49R viruses, some plaques produced by the U L 49-null virus were comparable in size to those produced by the wild-type virus (http://www.vet.cornell.edu/labs/baines/) after as few as two to three passages on noncomplementing cells. The reproducibility of these observations suggests that the U L 49-null virus somehow compensates for the lack of VP22 when propagated on noncomplementing cells. The mechanism of this phenotypic change is unknown but may reflect the acquisition of secondary mutations that compensate for the lack of VP22. Because phenotypic change may further define the function of VP22 during virus infection, as well as identify the basic mechanisms of HSV-1 spread, we are intrigued by this phenotypic morphogenesis, and studies are under way to identify its cause.
In the present work, studies were undertaken to determine the mechanism by which VP22 promotes viral spread. During multistep growth, both intracellular and extracellular U L 49 Ϫ PFU were reduced 11-fold compared to the WT and U L 49R viruses. Multistep growth experiments performed in the presence and absence of neutralizing antibody together with VP5 immunoblot-PFU and particle-PFU analyses of U L 49 Ϫ extracellular particle infectivity showed that this reduction was largely attributable to decreased levels of extracellular U L 49 Ϫ virus rather than to a defect in either U L 49
Ϫ virus assembly, cell-cell spread, or particle infectivity. At this time it is unclear whether the decreased extracellular virus observed during U L 49 Ϫ infection is due to a defect in viral exit from infected cells or decreased release of extracellular U L 49 Ϫ virions from intercellular spaces. The answer to this question and the role of VP22 in the mechanism(s) of viral exit and/or intercellular release will be the topics of future studies. Our present work shows that at least in some culture systems and tissue types, extracellular virus contributes greatly to viral spread, and VP22 plays a role in the accumulation of extracellular virus.
VP22 may promote extracellular virus accumulation and spread through a direct or indirect mode of action, and several possibilities exist for either scenario. For example, VP22 may affect the cytoskeleton of infected cells and promote efficient transport of virion-containing vesicles to the cell surface through its ability to stabilize microtubules (15) . Alternatively, VP22 may function indirectly through its interactions with and/or optimal incorporation of other viral proteins such as ICP0, gE, or gD into virions (7, 13, 20) . Elliott et al. have reported that in the absence of VP22 there is both a delay in the synthesis of the transactivator ICP0 and a complete loss of ICP0 virion incorporation (13) . If the decreased viral spread observed upon U L 49
Ϫ infection was due solely to these effects Ϫ (A to C), U L 49R (D to F), or WT HSV-1 (G to I) virus. At 24 or 48 hpi, the mice were sacrificed, and the corneas were dissected and prepared for immunohistochemistry using an antibody directed against HSV-1 proteins. Photographs of corneas flat mounted on glass slides are shown with the left and middle panels at the same magnification (bar ϭ 100 m) and at lower magnification in the right panels (bar ϭ 1 mm). on ICP0, one would expect to observe decreased production of intracellular virions, especially over several rounds of infection as measured by multistep growth, and/or decreased infectivity of U L 49 Ϫ virions. However, we did not observe either of these phenomena (Fig. 6, lower panel) . Another possibility is that VP22 mediates viral spread through incorporation of gD into virions. However, because HSV-1 gD is required for virus entry and our particle-PFU analyses did not show a measurable decrease in U L 49 Ϫ virion infectivity, it is unlikely that the decreased incorporation of gD into U L 49 Ϫ virions can fully explain the U L 49-null phenotype. Likewise, we observed decreased incorporation of gE into U L 49 Ϫ virions. However, gE is required for normal cell-cell spread (12) which was not decreased upon infection with the U L 49 Ϫ virus. Thus, while both gE and VP22 contribute to HSV-1 viral spread, VP22 appears to contribute through extracellular virus, whereas gE facilitates cell-cell spread.
Contribution of VP22 to herpetic disease. The spread of HSV between corneal epithelial cells is critical for two phases of herpetic eye disease. In the initial, primary phase, aerosolized HSV that has been released from one infected individual may enter a break in the corneal epithelium of a second individual. The virus replicates and spreads between epithelial cells of the second host, and it ultimately reaches the basal cell layer, where it can invade the fine axon endings of trigeminal ganglion cells. Within these axons HSV is transported retrograde to the ganglion cell bodies, where it can establish a latent infection. In the second phase following reactivation, new virus is transported anterograde within the nerve endings to the corneal epithelium (33) . The corneal epithelial cells again become infected, and the resulting humoral and cellular immunological responses may result in scarring and recurrent inflammation in the epithelium and deeper tissues (for review, see reference 41).
Understanding the pathogenesis of both phases of herpetic epithelial disease requires knowledge of the role(s) that viral genes play in viral spread. Because productive infection in animals may require specific viral proteins that are dispensable for replication in cultured cells, we considered it important to study the contribution of VP22 to HSV-1 infection in the context of the whole-animal model. Corneal lesions produced by the U L 49-null virus were dramatically reduced in size compared to those produced by the WT and UL49R viruses. Thus, we have identified a role for VP22 in HSV-1 corneal viral spread in vivo.
Studies on the contribution of VP22 to infection by other herpesviruses have shown variable importance for VP22 in viral growth and virulence. While a bovine herpesvirus U L 49 deletion virus exhibited a significant delay in single-step growth analyses and reduced virulence in cattle (26, 27) , a PRV U L 49 deletion virus showed single-step growth profiles identical to WT PRV and did not promote virulence or neuroinvasiveness in the rat eye infection model (11) . Together, these data indicate that the presence of VP22 is of variable importance to different herpesviruses and experimental systems.
In summary, we have characterized the growth of an HSV-1 U L 49-null virus and have identified a role for VP22 in viral spread during HSV-1 infection both in vitro and in vivo. Future studies will identify how this protein functions to promote viral spread and determine whether VP22 plays a role in virion exit and/or intercellular release. In addition, the use of a U L 49-null virus with its genetically repaired partner should greatly facilitate investigations of the involvement of VP22 in HSV-1 tegument formation, pathogenesis, and virion egress.
